ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Aurora B/VEGFR/FGFR Inhibitor AL8326

Also written as “AL8326 tablets”, “AL8326 40 mg” and “AL8326 60 mg”.

Its studies are mostly in Small Cell Lung Carcinoma · Carcinoma, Non-Small-Cell Lung, led by 3 companies.

Drug pageAurora B/VEGFR/FGFR Inhibitor AL8326: every studyAll 7 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 9, 20238 company-led studies, 4 open or runningNext primary completion: Dec 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Advenchen Laboratories Nanjingits history only51 open or runningphase 3since Oct 9, 2023Apr 26, 2021Jul 2028phase 3 · NCT06247605
Advenchen Laboratories22 open or runningphase 2since Sep 28, 2025Jan 30, 2024Dec 2027phase 1 · NCT06794957
Advenchen Pharmaceuticals, LLC.its history only11 open or runningphase 2since Apr 22, 2022Apr 22, 2022Dec 2027phase 2 · NCT05363280

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Advenchen Laboratories only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 30, 2024First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT06794957 · 158 enrolled · China
  2. Sep 28, 2025Phase 2 study in Solid TumorNCT07392736 · 228 planned · China

Ahead

  1. Dec 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT06794957
  2. Nov 7, 2029Primary completion: phase 2 study in Solid TumorNCT07392736

TargetBeta

KDR →read by rule
“An orally bioavailable inhibitor of the receptor kinases Aurora B, fibroblast growth factor receptor (FGFR), and vascular endothelial growth factor receptor (VEGFR), ”NCIt, by rule

Other programs on KDR

ProgramCompanyFurthest phaseStudies
lenvatinibruleEisaiphase 481
nintedanibruleBoehringer Ingelheimphase 476
regorafenibruleBayerphase 440
cabozantinibruleExelixisphase 436
RamucirumabruleEli Lillyphase 358
apatinibruleJiangsu HengRui Medicinephase 347
AxitinibrulePfizerphase 345
anlotinibruleSino Biopharmaceuticalphase 340
vorolanibruleBetta Pharmaceuticalsphase 324
zanzalintinibruleExelixisphase 317
chiauranibruleChipscreen Biosciencesphase 315
AXL/FLT3/VEGFR2 Inhibitor KC1036rulebeijing-konruns-pharmaceutical-co-ltdphase 37

Studies

All 2 Advenchen Laboratories leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07392736Solid Tumor · China2RecruitingNov 7, 2029228
NCT06794957Carcinoma, Non-Small-Cell Lung · China1Active, not recruitingDec 2027158

How it is read

Names in the registry

  • “AL8326 tablets”, 6 entries
  • “AL8326 40 mg”, 1 entry
  • “AL8326 60 mg”, 1 entry
  • “AL8326 80 mg--stopped”, 1 entry
  • “14C-labeled AL8326”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.